新辅助抗PD-1治疗可切除非小细胞肺癌的病理缓解特征:免疫相关病理缓解标准(irPRC)的提出
该研究基于新辅助抗PD-1(纳武利尤单抗)治疗后手术切除的20例NSCLC标本,分析病理缓解特征并提出免疫相关病理缓解标准(irPRC)。研究发现回归床具有免疫激活、肿瘤细胞死亡和组织修复三重特征,且irPRC在病理学家间可重复性优于化疗相关标准。irPRC可用于标准化免疫治疗疗效的病理评估,但需长期随访验证其作为生存替代指标的可靠性。
要点
- irPRC基于回归床的三类组织学特征制定,在病理学家间具有可重复性。
- irRVT的观察者间一致性优于cRVT,中位每例变异度和标准差均更低。
- irPRC可用于标准化新辅助免疫治疗病理疗效评估,但需长期随访验证。
核心结论
- irPRC可用于标准化免疫治疗疗效的病理评估。
- irPRC作为无复发生存和总生存替代指标的可靠性尚需长期随访确定。
研究设计与样本
- 分析新辅助抗PD-1(纳武利尤单抗,NCT02259621)治疗后 definitive 手术切除的20例NSCLC患者的HE染色切片。
- 同时评估治疗前肿瘤活检和切除前影像学「肿瘤」测量。
主要发现
- 回归床(免疫介导肿瘤清除区域)可解释CT影像与病理评估残留肿瘤之间的差异。
- 回归床特征包括:免疫激活(密集TIL伴巨噬细胞和三级淋巴结构)、大量肿瘤细胞死亡(胆固醇裂隙)、组织修复(新生血管化和增生性纤维化)。
- 上述每个特征在主要病理缓解者中较非缓解者富集(P < 0.05)。
- 该组组织学表现未在任何治疗前标本中识别。
- %irRVT的观察者间一致性优于%cRVT:中位每例%RVT变异度5%(0%-29%)vs 10%(0%-58%),P = 0.007;中位标准差2.2 vs 4.6,P = 0.002。
关键数值与推荐
- 主要病理缓解定义为残留存活肿瘤(RVT)≤10%。
- irPRC基于回归床的组织学特征制定,在病理学家间可重复。
临床怎么用
- 病理评估新辅助免疫治疗疗效时可参考irPRC标准,以提高观察者间一致性。
- 需注意回归床特征可能造成影像与病理残留肿瘤评估的差异。
局限性
- 样本量小(20例手术患者)。
- irPRC作为生存替代指标的可靠性尚未经长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as ≤10% residual viable tumor (RVT), may predict improved long-term patient outcome. However, %RVT calculations were developed in the context of chemotherapy (%cRVT). An immune-related %RVT (%irRVT) has yet to be developed. PATIENTS AND METHODS: The first trial of neoadjuvant anti-PD-1 (nivolumab, NCT02259621) was just reported. We analyzed hematoxylin and eosin-stained slides from the post-treatment resection specimens of the 20 patients with non-small-cell lung carcinoma who underwent definitive surgery. Pretreatment tumor biopsies and preresection radiographic 'tumor' measurements were also assessed. RESULTS: We found that the regression bed (the area of immune-mediated tumor clearance) accounts for the previously noted discrepancy between CT imaging and pathologic assessment of residual tumor. The regression bed is characterized by (i) immune activation-dense tumor infiltrating lymphocytes with macrophages and tertiary lymphoid structures; (ii) massive tumor cell death-cholesterol clefts; and (iii) tissue repair-neovascularization and proliferative fibrosis (each feature enriched in major pathologic responders versus nonresponders, P < 0.05). This distinct constellation of histologic findings was not identified in any pretreatment specimens. Histopathologic features of the regression bed were used to develop 'Immune-Related Pathologic Response Criteria' (irPRC), and these criteria were shown to be reproducible amongst pathologists. Specifically, %irRVT had improved interobserver consistency compared with %cRVT [median per-case %RVT variability 5% (0%-29%) versus 10% (0%-58%), P = 0.007] and a twofold decrease in median standard deviation across pathologists within a sample (4.6 versus 2.2, P = 0.002). CONCLUSIONS: irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.
引用
- Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018. PMID: 29982279. doi:10.1093/annonc/mdy218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。